# Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

> **NCT00874588** · PHASE1 · COMPLETED · sponsor: **Fukushima Medical University** · enrollment: 6 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2

## Key facts

- **NCT ID:** NCT00874588
- **Lead sponsor:** Fukushima Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2013-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00874588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00874588, "Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00874588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*